期刊文献+

急性髓系白血病患者血清β2-MG、HGF、TGFβ1表达及临床意义 被引量:22

The Expressions of Serumβ2-MG,HGF and TGFβ1 in Patients with Acute Myeloid Leukemia and Their Clinical Significances
下载PDF
导出
摘要 目的探讨急性髓系白血病(AML)患者血清β2微球蛋白(β2-MG)、肝细胞生长因子(HGF)、转化生长因子-β1(TGF-β1)表达及临床意义。方法以2010年1月至2018年1月我院诊治的96例AML患者作为疾病组、同期健康体检的35名志愿者作为健康组,比较两组血清β2-MG、HGF、TGFβ1表达水平,分析不同病理特征、不同疗效AML患者血清β2-MG、HGF、TGFβ1表达水平,并进行相关性分析。结果与健康组比较,疾病组血清β2-MG、HGF水平明显升高,而TGFβ1水平明显降低,差异具有统计学意义(P<0.05);复发、异常染色体核型AML患者血清β2-MG、HGF明显高于无复发、正常染色体核型者,而TGFβ1水平明显低于无复发、正常染色体核型者(P<0.05),AML完全缓解者血清β2-MG、HGF明显低于未缓解者,TGFβ1水平则明显高于未缓解者(P<0.05),Pearson相关分析提示AML患者疗效与血清β2-MG、HGF呈明显负相关(r=-0.456、-0.462),与TGFβ1水平呈明显正相关(r=0.498),而复发率与血清β2-MG、HGF呈明显正相关(r=0.468、0.511),与TGFβ1呈明显负相关(r=-0.568)(均P<0.05)。结论AML患者血清β2-MG、HGF呈高表达而TGFβ1呈低表达,三者与AML患者化疗疗效、预后密切相关,或可作为AML早期诊治的有效标志物。 Objective To explore expressions of serumβ2 microglobulin(β2-MG),hepatocyte growth factor(HGF)and transforming growth factor-β1(TGF-β1)in patients with acute myeloid leukemia(AML)and their clinical significances.Methods 96 AML patients who were diagnosed and treated in the hospital from January,2010 to January,2018 were enrolled as the disease group,while 35 healthy volunteers who underwent physical examination during the same period were enrolled as the healthy group.The levels of serumβ2-MG,HGF and TGFβ1 were compared between the two groups.The expression levels of serumβ2-MG,HGF and TGFβ1 among AML patients with different pathological features and curative effect were analyzed.And a correlation analysis was also performed.Results Compared with the healthy group,levels of serumβ2-MG and HGF were significantly increased in the disease group,while level of TGFβ1 was significantly decreased(P<0.05).The levels of serumβ2-MG and HGF in AML patients with recurrence and abnormal karyotype were significantly higher than those without recurrence and with normal karyotype,while level of TGFβ1 was significantly lower than that without recurrence and with normal karyotype(P<0.05).The levels of serumβ2-MG and HGF in AML patients with complete remission were significantly lower than those without remission,while level of TGFβ1 was significantly higher than those without remission(P<0.05).Pearson correlation analysis indicated that curative effect of AML patients was significantly negatively correlated with serumβ2-MG and HGF(r=-0.456,-0.462),while significantly positively correlated with TGFβ1 level(r=0.498).The recurrence rate was significantly positively correlated with serumβ2-MG and HGF,(r=0.468,0.511),while significantly negatively correlated with TGFβ1(r=-0.568)(P<0.05).Conclusion Relative to healthy subjects,the serumβ2-MG and HGF of AML patients are highly expressed,while TGFβ1 is lowly expressed.These three markers are closely related to curative effect of chemotherapy and prognosis in AML patien
作者 任丽蓉 官晓红 练颖 胡谦 陶黎 雷丽华 REN Lirong;GUAN Xiaohong;LIAN Ying;HU Qian;TAO Li;LEI Lihua(Department of Hematology, Chengdu Integrated Traditional Chinese and Western Medicine Hospital, Chengdu 610000, China)
出处 《标记免疫分析与临床》 CAS 2020年第3期488-492,共5页 Labeled Immunoassays and Clinical Medicine
基金 四川省科技厅科技支撑计划(编号:2012SZ01409)。
关键词 急性髓系白血病 Β2-MG HGF TGFΒ1 临床意义 Acute myeloid leukemia β2-MG HGF TGFβ1 Clinical significance
  • 相关文献

参考文献12

二级参考文献120

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量:7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 3江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量:39
  • 4O' Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Cane Netw, 2009, 7:982-1023. 被引量:1
  • 5NCCN Clinical Practice Guidelines in Oncology (NCCN Guide- lines^TM )-FREE: Chronic Myelogenous Leukemia. Version 2. 2011[ 2011-03-29 ]. http//www. nccn. org/professionals/physi- cian_gls/f_guidelines. asp. 被引量:1
  • 6Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic mycloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108 : 1809-1820. 被引量:1
  • 7Baccarani M,Cortes J,Pane F, et al. Chronic myeloid leukemia, an update of concepts and management Recommendations of the Euro- peanLeukemiaNet. J Clin Oncol, 2009, 27:6041-6051. 被引量:1
  • 8World Health Organization Classification of Tumors. Pathology and Genetic of Tumors of Haematopoietic and Lymphoid Tissue. 2008. 被引量:1
  • 9Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol, 1988,25:49-61. 被引量:1
  • 10Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic my- elogenous leukemia. N Engl J Med, 2007,357:258-265. 被引量:1

共引文献185

同被引文献199

引证文献22

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部